Move to topTop
September 17, 2021

Following the recent approval by the US Food and Drug Administration (FDA) of the RelayPro Thoracic Stent-Graft System for the treatment of patients with fusiform and saccular aneurysms, and penetrating atherosclerotic ulcers (PAUs) in the descending thoracic aorta, Terumo Aortic announced today the first commercial implants of this device in the United States.

The implants were performed by the Co-National Principal Investigators of the pivotal RelayPro aneurysm study, namely, Venkatesh G Ramaiah MD, Chief of Vascular and Endovascular Surgery, Honor Health Network, Scottsdale, Arizona, US, and Wilson Y Szeto MD, Chief of Cardiovascular Surgery, Penn Presbyterian University of Pennsylvania Health System, Philadelphia, US.

Venkatesh G Ramaiah commented: "The low profile delivery system is designed to accommodate patients with smaller access vessels. The platform utilises the same stent design, materials and dual sheath technology of the proven RelayPlus system delivering the accuracy, control and confidence of RelayPlus without compromising device integrity and durability."

Wilson Y Szeto added: "RelayPro is the only lower profile device with a Non-Bare Stent design available in the United States to treat aneurysms and penetrating atherosclerotic ulcers. The unique technology incorporated into the delivery system is integral to securing optimal wall apposition and allows for the effective treatment of patients with thoracic aneurysms."

Paul Kuznik, President of Terumo Aortic North America, said: "This commercial implant represents a significant milestone for the company as we embark upon delivering the most comprehensive device portfolio within the aortic space."

RelayPro received CE Mark in 2017 and FDA approval in 2021; it is integral to Terumo Aortic's market leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.

About Terumo Aortic

At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.